retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Synedica Retatrutide | Triple Agonist

Patients on GLP-1 medications should hold daily doses on the day of the procedure and weekly doses seven days prior to surgery

DISCUSSION In this NMA, GLP-1RA had a significantly better effect in reducing liver fat content and improving cardiometabolic risk parameters, including BMI and WC, in overweight or obese patients with NAFLD or NASH

DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice

The systems that matter most for dementia prevention In longevity medicine, the practical question is not whether one therapy is good for the brain. The better question is whether the persons overall biology is moving toward resilience or vulnerability